Prediction of Radio-responsiveness with Immune-profiling in Patients with Rectal Cancer
Overview
Authors
Affiliations
We evaluate whether the tumor immune infiltrate (TIL) could be used for prediction of responsiveness to preoperative chemoradiotherapy (PCRT) in rectal cancers. Using formalin-fixed paraffin-embedded slides of pretreatment biopsies, co-stain for CD4, CD8, CD274 (PD-L1), FOXP3, cytokeratin, and DAPI was performed with (Perkin-Elmer, Waltham, MA). Multispectral imaging and digital analysis to visualize and quantify specific immune infiltrates were performed using the (Perkin-Elmer). The density (number of cells per mm) and proportion of total TILs and specific cell types in the stroma were calculated by inForm™ 2.2.1 software (Perkin-Elmer). The density and proportion of total TILs and specific cell types in the stroma were calculated by inForm™ 2.2.1 software (Perkin-Elmer, Waltham, MA). Patients were classified as group with total regression (TR, = 25) and group with residual disease (near total, moderate, and minimal regression, RD, 50). The mean density of T cell infiltration and CD274 (PD-L1)+ lymphocyte were significantly higher in TR ( = 0.005, = 0.001). The proportion of CD4+ lymphocyte (p=0.042) and CD274 (PD-L1)+ lymphocyte ( = 0.002) were different between 2 groups. The TR group has lower CD4+ and higher CD274 (PD-L1)+ proportions than RD group. The ratio among CD4+, CD8+, CD274 (PD-L1)+, FOXP3+ T cell was different between groups. TR group showed lower CD4/ CD274 (PD-L1) ( = 0.007), CD8/ CD274 (PD-L1) ( = 0.02), and FOXP3/ CD274 (PD-L1) ( = 0.003) ratio than RD group. The determination of the immune infiltrate in biopsies before treatment could be a valuable information for the prediction of responsiveness to PCRT.
Hwang J, Kim S, Bang H, Kim H, Shim H, Bae W Cancers (Basel). 2024; 16(19).
PMID: 39409972 PMC: 11475605. DOI: 10.3390/cancers16193353.
Shu P, Liu N, Luo X, Tang Y, Chen Z, Li D Front Oncol. 2024; 14:1294440.
PMID: 38406803 PMC: 10889124. DOI: 10.3389/fonc.2024.1294440.
Tse B, Bergamin S, Steffen P, Hruby G, Pavlakis N, Clarke S Oncoimmunology. 2023; 12(1):2238506.
PMID: 37485033 PMC: 10361136. DOI: 10.1080/2162402X.2023.2238506.
Koukourakis I, Platoni K, Tiniakos D, Kouloulias V, Zygogianni A Curr Issues Mol Biol. 2023; 45(5):4495-4517.
PMID: 37232754 PMC: 10216994. DOI: 10.3390/cimb45050285.
Shinohara H, Kobayashi M, Hayashi K, Nogawa D, Asakawa A, Ohata Y Int J Mol Sci. 2022; 23(21).
PMID: 36362023 PMC: 9656504. DOI: 10.3390/ijms232113235.